Insulin Receptor Substrates Are Essential for the Bioenergetic and Hypertrophic Response of the Heart to Exercise Training

REFERENCES

• Abel ED, Doenst T. 2011. Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy. Cardiovasc. Res. 90:234–242. http://dx.doi.org/10.1093/cvr/cvr015.
   PubMed Web of Science ®Google Scholar
• Dorn GWII. 2007. The fuzzy logic of physiological cardiac hypertrophy. Hypertension 49:962–970. http://dx.doi.org/10.1161/HYPERTENSIONAHA.106.079426.
   PubMed Web of Science ®Google Scholar
• Shiojima I, Walsh K. 2006. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev. 20:3347–3365. http://dx.doi.org/10.1101/gad.1492806.
   PubMed Web of Science ®Google Scholar
• Belke DD, Betuing S, Tuttle MJ, Graveleau C, Young ME, Pham M, Zhang D, Cooksey RC, McClain DA, Litwin SE, Taegtmeyer H, Severson D, Kahn CR, Abel ED. 2002. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J. Clin. Invest. 109:629–639. http://dx.doi.org/10.1172/JCI13946.
   PubMed Web of Science ®Google Scholar
• Kim J, Wende AR, Sena S, Theobald HA, Soto J, Sloan C, Wayment BE, Litwin SE, Holzenberger M, LeRoith D, Abel ED. 2008. Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol. Endocrinol. 22:2531–2543. http://dx.doi.org/10.1210/me.2008-0265.
   PubMedGoogle Scholar
• Boudina S, Bugger H, Sena S, O'Neill BT, Zaha VG, Ilkun O, Wright JJ, Mazumder PK, Palfreyman E, Tidwell TJ, Theobald H, Khalimonchuk O, Wayment B, Sheng X, Rodnick KJ, Centini R, Chen D, Litwin SE, Weimer BE, Abel ED. 2009. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 119:1272–1283. http://dx.doi.org/10.1161/CIRCULATIONAHA.108.792101.
   PubMed Web of Science ®Google Scholar
• Neri Serneri GG, Boddi M, Modesti PA, Cecioni I, Coppo M, Padeletti L, Michelucci A, Colella A, Galanti G. 2001. Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ. Res. 89:977–982. http://dx.doi.org/10.1161/hh2301.100982.
   PubMedGoogle Scholar
• Scheinowitz M, Kessler-Icekson G, Freimann S, Zimmermann R, Schaper W, Golomb E, Savion N, Eldar M. 2003. Short- and long-term swimming exercise training increases myocardial insulin-like growth factor-I gene expression. Growth Horm. IGF Res. 13:19–25. http://dx.doi.org/10.1016/S1096-6374(02)00137-5.
   PubMed Web of Science ®Google Scholar
• DeBosch B, Treskov I, Lupu TS, Weinheimer C, Kovacs A, Courtois M, Muslin AJ. 2006. Akt1 is required for physiological cardiac growth. Circulation 113:2097–2104. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.595231.
   PubMed Web of Science ®Google Scholar
• McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM, Izumo S. 2003. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 100:12355–12360. http://dx.doi.org/10.1073/pnas.1934654100.
   PubMed Web of Science ®Google Scholar
• McMullen JR, Shioi T, Huang WY, Zhang L, Tarnavski O, Bisping E, Schinke M, Kong S, Sherwood MC, Brown J, Riggi L, Kang PM, Izumo S. 2004. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J. Biol. Chem. 279:4782–4793. http://dx.doi.org/10.1074/jbc.M310405200.
   PubMed Web of Science ®Google Scholar
• O'Neill BT, Kim J, Wende AR, Theobald HA, Tuinei J, Buchanan J, Guo A, Zaha VG, Davis DK, Schell JC, Boudina S, Wayment B, Litwin SE, Shioi T, Izumo S, Birnbaum MJ, Abel ED. 2007. A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy. Cell Metab. 6:294–306. http://dx.doi.org/10.1016/j.cmet.2007.09.001.
   PubMedGoogle Scholar
• Araki E, Lipes MA, Patti ME, Bruning JC, Haag BIII, Johnson RS, Kahn CR. 1994. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372:186–190. http://dx.doi.org/10.1038/372186a0.
   PubMed Web of Science ®Google Scholar
• Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, Terauchi Y, Ueki K, Kaburagi Y, Satoh S, Sekihara H, Yoshioka S, Horikoshi H, Furuta Y, Ikawa Y, Kasuga M, Yazaki Y, Aizawa S. 1994. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372:182–186. http://dx.doi.org/10.1038/372182a0.
   PubMed Web of Science ®Google Scholar
• Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF. 1998. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900–904. http://dx.doi.org/10.1038/36116.
   PubMed Web of Science ®Google Scholar
• Abel ED, Kaulbach HC, Tian R, Hopkins JC, Duffy J, Doetschman T, Minnemann T, Boers ME, Hadro E, Oberste-Berghaus C, Quist W, Lowell BB, Ingwall JS, Kahn BB. 1999. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J. Clin. Invest. 104:1703–1714. http://dx.doi.org/10.1172/JCI7605.
   PubMed Web of Science ®Google Scholar
• Dong XC, Copps KD, Guo S, Li Y, Kollipara R, DePinho RA, White MF. 2008. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab. 8:65–76. http://dx.doi.org/10.1016/j.cmet.2008.06.006.
   PubMed Web of Science ®Google Scholar
• Lin X, Taguchi A, Park S, Kushner JA, Li F, Li Y, White MF. 2004. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J. Clin. Invest. 114:908–916. http://dx.doi.org/10.1172/JCI22217.
   PubMed Web of Science ®Google Scholar
• Riehle C, Wende AR, Zaha VG, Pires KM, Wayment B, Olsen C, Bugger H, Buchanan J, Wang X, Moreira AB, Doenst T, Medina-Gomez G, Litwin SE, Lelliott CJ, Vidal-Puig A, Abel ED. 2011. PGC-1beta deficiency accelerates the transition to heart failure in pressure overload hypertrophy. Circ. Res. 109:783–793. http://dx.doi.org/10.1161/CIRCRESAHA.111.243964.
   PubMed Web of Science ®Google Scholar
• Sena S, Rasmussen IR, Wende AR, McQueen AP, Theobald HA, Wilde N, Pereira RO, Litwin SE, Berger JP, Abel ED. 2007. Cardiac hypertrophy caused by peroxisome proliferator-activated receptor-gamma agonist treatment occurs independently of changes in myocardial insulin signaling. Endocrinology 148:6047–6053. http://dx.doi.org/10.1210/en.2006-1559.
   PubMed Web of Science ®Google Scholar
• Riehle C, Wende AR, Sena S, Pires KM, Pereira RO, Zhu Y, Bugger H, Frank D, Bevins J, Chen D, Perry CN, Dong XC, Valdez S, Rech Sheng MX, Weimer BC, Gottlieb RA, White MF, Abel ED. 2013. Insulin receptor substrate signaling suppresses neonatal autophagy in the heart. J. Clin. Invest. 123:5319–5333. http://dx.doi.org/10.1172/JCI71171.
   PubMed Web of Science ®Google Scholar
• Haemmerle G, Moustafa T, Woelkart G, Buttner S, Schmidt A, van de Weijer T, Hesselink M, Jaeger D, Kienesberger PC, Zierler K, Schreiber R, Eichmann T, Kolb D, Kotzbeck P, Schweiger M, Kumari M, Eder S, Schoiswohl G, Wongsiriroj N, Pollak NM, Radner FP, Preiss-Landl K, Kolbe T, Rulicke T, Pieske B, Trauner M, Lass A, Zimmermann R, Hoefler G, Cinti S, Kershaw EE, Schrauwen P, Madeo F, Mayer B, Zechner R. 2011. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat. Med. 17:1076–1085. http://dx.doi.org/10.1038/nm.2439.
   PubMed Web of Science ®Google Scholar
• Wende AR, Schaeffer PJ, Parker GJ, Zechner C, Han DH, Chen MM, Hancock CR, Lehman JJ, Huss JM, McClain DA, Holloszy JO, Kelly DP. 2007. A role for the transcriptional coactivator PGC-1alpha in muscle refueling. J. Biol. Chem. 282:36642–36651. http://dx.doi.org/10.1074/jbc.M707006200.
   PubMed Web of Science ®Google Scholar
• Hardt SE, Sadoshima J. 2002. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ. Res. 90:1055–1063. http://dx.doi.org/10.1161/01.RES.0000018952.70505.F1.
   PubMed Web of Science ®Google Scholar
• Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N. 1999. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13:1422–1437. http://dx.doi.org/10.1101/gad.13.11.1422.
   PubMed Web of Science ®Google Scholar
• Chen J, Parsons S, Brautigan DL. 1994. Tyrosine phosphorylation of protein phosphatase 2A in response to growth stimulation and v-src transformation of fibroblasts. J. Biol. Chem. 269:7957–7962.
   PubMedGoogle Scholar
• Chen J, Martin BL, Brautigan DL. 1992. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 257:1261–1264. http://dx.doi.org/10.1126/science.1325671.
   PubMed Web of Science ®Google Scholar
• Ugi S, Imamura T, Maegawa H, Egawa K, Yoshizaki T, Shi K, Obata T, Ebina Y, Kashiwagi A, Olefsky JM. 2004. Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol. Cell. Biol. 24:8778–8789. http://dx.doi.org/10.1128/MCB.24.19.8778-8789.2004.
   PubMed Web of Science ®Google Scholar
• Yokoyama N, Reich NC, Miller WT. 2003. Determinants for the interaction between Janus kinase 2 and protein phosphatase 2A. Arch. Biochem. Biophys. 417:87–95. http://dx.doi.org/10.1016/S0003-9861(03)00333-3.
   PubMedGoogle Scholar
• Argetsinger LS, Kouadio JL, Steen H, Stensballe A, Jensen ON, Carter-Su C. 2004. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol. Cell. Biol. 24:4955–4967. http://dx.doi.org/10.1128/MCB.24.11.4955-4967.2004.
   PubMed Web of Science ®Google Scholar
• Simon AR, Vikis HG, Stewart S, Fanburg BL, Cochran BH, Guan KL. 2000. Regulation of STAT3 by direct binding to the Rac1 GTPase. Science 290:144–147. http://dx.doi.org/10.1126/science.290.5489.144.
   PubMed Web of Science ®Google Scholar
• Burelle Y, Wambolt RB, Grist M, Parsons HL, Chow JC, Antler C, Bonen A, Keller A, Dunaway GA, Popov KM, Hochachka PW, Allard MF. 2004. Regular exercise is associated with a protective metabolic phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 287:H1055–H1063. http://dx.doi.org/10.1152/ajpheart.00925.2003.
   PubMedGoogle Scholar
• Luo J, McMullen JR, Sobkiw CL, Zhang L, Dorfman AL, Sherwood MC, Logsdon MN, Horner JW, DePinho RA, Izumo S, Cantley LC. 2005. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol. Cell. Biol. 25:9491–9502. http://dx.doi.org/10.1128/MCB.25.21.9491-9502.2005.
   PubMedGoogle Scholar
• Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, Izumo S. 2000. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19:2537–2548. http://dx.doi.org/10.1093/emboj/19.11.2537.
   PubMed Web of Science ®Google Scholar
• Ikeda H, Shiojima I, Ozasa Y, Yoshida M, Holzenberger M, Kahn CR, Walsh K, Igarashi T, Abel ED, Komuro I. 2009. Interaction of myocardial insulin receptor and IGF receptor signaling in exercise-induced cardiac hypertrophy. J. Mol. Cell. Cardiol. 47:664–675. http://dx.doi.org/10.1016/j.yjmcc.2009.08.028.
   PubMed Web of Science ®Google Scholar
• Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR. 2004. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J. Biol. Chem. 279:32771–32779. http://dx.doi.org/10.1074/jbc.M403528200.
   PubMed Web of Science ®Google Scholar
• Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, Goodyear LJ, Iannacone M, Accili D, Cantley LC, Kahn CR. 2002. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J. Clin. Invest. 109:141–149. http://dx.doi.org/10.1172/JCI13305.
   PubMed Web of Science ®Google Scholar
• Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, Saffitz JE, Abel ED, Semenkovich CF, Kelly DP. 2005. PGC-1alpha deficiency causes multisystem energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 3:e101. http://dx.doi.org/10.1371/journal.pbio.0030101.
   PubMed Web of Science ®Google Scholar